Effect of Dapagliflozin on Secondary Mitral Regurgitation
Dilated Cardiomyopathy
About this trial
This is an interventional treatment trial for Dilated Cardiomyopathy
Eligibility Criteria
Inclusion Criteria: Outpatients ≥ 18 years of age Dilated LV with a reduced ejection fraction and secondary functional MR NYHA functional class II or III Moderate to Severe MR which lasted > 6 months under medical treatment with a β-blocker and an ACE inhibitor (or ARB) Exclusion Criteria: Current use or prior use of Dapagliflozin Current acute heart failure or prior admission with acute decompensated heart failure in 6 months before entry to study NYHA functional class IV Chronic renal impairment with GFR < 30 mL/min/1.73m2 Pregnant or lactating women History of allergy to Dapagliflozin
Sites / Locations
- Beni-suef UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Experimental
Control
Interventional
Group 1 received only standard therapy ACE/ ARB, BB, and diuretics
Group 2 received dapagliflozin 10 mg once daily in addition to standard therapy ACE/ ARB, BB, and diuretics